NCT06553456View on ClinicalTrials.gov

Phase II/III Clinical Trial of Recombinant Human Serum Albumin in Cirrhotic Patients With Ascites

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

390

Participants

Timeline

Start Date

August 13, 2024

Primary Completion Date

May 14, 2025

Study Completion Date

May 14, 2025

Conditions
Cirrhotic Ascites
Interventions
DRUG

Recombinant Human Serum Albumin

The experimental drug was administered at a dose of 20 g/ day for 7 days.

DRUG

Human Serum Albumin

The positive control drug was administered at a dose of 20 g/ day for 7 days.

Trial Locations (1)

10084

Shenzhen Protgen Ltd, Guangdong

All Listed Sponsors
lead

Protgen Ltd

INDUSTRY

NCT06553456 - Phase II/III Clinical Trial of Recombinant Human Serum Albumin in Cirrhotic Patients With Ascites | Biotech Hunter | Biotech Hunter